Mutual of America Capital Management LLC Decreases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mutual of America Capital Management LLC trimmed its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.2% during the 4th quarter, Holdings Channel reports. The fund owned 38,895 shares of the specialty pharmaceutical company’s stock after selling 2,138 shares during the period. Mutual of America Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $4,784,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. US Bancorp DE raised its holdings in Jazz Pharmaceuticals by 13.3% during the 1st quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 322 shares during the period. Private Advisor Group LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $547,000. Aviva PLC raised its holdings in Jazz Pharmaceuticals by 87.1% during the 1st quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock valued at $6,228,000 after buying an additional 18,628 shares during the period. Allianz Asset Management GmbH raised its holdings in Jazz Pharmaceuticals by 118.2% during the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after buying an additional 6,571 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after buying an additional 57,949 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $110.58 on Monday. Jazz Pharmaceuticals plc has a 12-month low of $110.42 and a 12-month high of $147.14. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The business’s fifty day simple moving average is $121.21 and its 200-day simple moving average is $123.09. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 1.53 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. On average, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent research reports. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. Piper Sandler upped their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. UBS Group cut their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Finally, Barclays cut their price objective on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.